Lanham O'Dell & Company’s Catalyst Pharmaceutical CPRX Stock Holding History

Lanham O'Dell & Company’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$280K	Sell	12,000 -2,000	-14%	-$44.6K	0.08%	27
2025 Q3	$276K	Hold	14,000	–	–	0.09%	26
2025 Q2	$304K	Sell	14,000 -1,000	-7%	-$23.6K	0.13%	21
2025 Q1	$364K	Hold	15,000	–	–	0.21%	14
2024 Q4	$313K	Sell	15,000 -2,000	-12%	-$43K	0.17%	16
2024 Q3	$338K	Sell	17,000 -3,000	-15%	-$55.6K	0.19%	16
2024 Q2	$310K	Hold	20,000	–	–	0.17%	19
2024 Q1	$319K	Sell	20,000 -645	-3%	-$9.72K	0.16%	22
2023 Q4	$347K	Sell	20,645 -355	-2%	-$4.85K	0.24%	21
2023 Q3	$245K	Hold	21,000	–	–	0.2%	15
2023 Q2	$282K	Hold	21,000	–	–	0.26%	13
2023 Q1	$348K	Buy	21,000 +1,000	+5%	+$16.5K	0.38%	13
2022 Q4	$372K	Sell	20,000 -145	-0.7%	-$2.23K	0.81%	12
2022 Q3	$258K	Buy	+20,145	New	+$239K	0.92%	24
2022 Q2	–	Sell	-26,500	Closed	-$220K	–	20
2022 Q1	$220K	Sell	26,500 -23,500	-47%	-$166K	0.17%	17
2021 Q4	$339K	Buy	+50,000	New	+$329K	0.27%	14

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lanham O'Dell & Company's CPRX Position: Q4 2025 in Review

Lanham O'Dell & Company reduced its Catalyst Pharmaceutical (CPRX) stake by 14% in Q4 2025, selling an estimated $44.6K and leaving 12,000 shares worth $280K. The position accounts for 0.08% of the portfolio, ranked #27.

Lanham O'Dell & Company first reported a position in CPRX in Q4 2021 and has held it in 16 quarters since. The position peaked at $372K in Q4 2022. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

Lanham O'Dell & Company held 12,000 shares of Catalyst Pharmaceutical worth $280K as of Q4 2025.
Lanham O'Dell & Company sold 2,000 Catalyst Pharmaceutical shares in Q4 2025, an estimated $44.6K.
Catalyst Pharmaceutical made up 0.08% of Lanham O'Dell & Company's portfolio in Q4 2025, its #27 holding.
Lanham O'Dell & Company first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 16 quarters since.
Lanham O'Dell & Company's Catalyst Pharmaceutical position peaked at $372K in Q4 2022.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Lanham O'Dell & Company's 13F filing for Q4 2025, filed 12 Jan 2026.